首页> Acta reumatologica portuguesa> Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.

Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.

导出 LinkOut

翻译打印收藏纠错

第一作者： Daniela,Santos-Faria

第一单位： Hospital Conde de Bertiandos - Unidade Local de Saúde do Alto Minho, Ponte de Lima.

作者： Daniela,Santos-Faria ^[1] ; José,Tavares-Costa ^[1] ; Mónica,Eusébio ^[1] ; Joana,Leite Silva ^[1] ; Joana,Ramos Rodrigues ^[1] ; Joana,Sousa-Neves ^[2] ; Ana Catarina,Duarte ^[3] ; Carina,Lopes ^[4] ; Ana,Valido ^[4] ; Joana,Dinis ^[5] ; João,Freitas ^[5] ; Mariana,Santiago ^[6] ; Raquel,Ferreira ^[6] ; Sara,Ganhão ^[7] ; Luís,Miranda ^[1] ; Daniela,Peixoto ^[1] ; Filipa,Teixeira ^[1] ; Sérgio,Alcino ^[1] ; Carmo,Afonso ^[2] ; Maria José,Santos

作者单位： Hospital Conde de Bertiandos - Unidade Local de Saúde do Alto Minho, Ponte de Lima. ^[1] Hospital Garcia de Orta, Almada. ^[2] Hospital de Egas Moniz - CHLO, Lisbon. ^[3] Centro Hospitalar Lisboa Norte, Lisbon. ^[4] Centro Hospitalar e Universitário de Coimbra, Coimbra. ^[5] Centro Hospitalar de São João, Porto. ^[6] Instituto Português de Reumatologia, Lisbon. ^[7]